Currently out of the existing stock ratings of Terence Flynn, 186 are a HOLD (42.37%), 39 are a SELL (8.88%), 214 are a BUY (48.75%).

Terence Flynn

Work Performance Price Targets & Ratings Chart

Analyst Terence Flynn, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 66.27% that have a potential upside of 24.77% achieved within 238 days.

Terence Flynn’s has documented 950 price targets and ratings displayed on 43 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CRSP, Crispr Therapeutics AG at 11-Jun-2026.

Wall Street Analyst Terence Flynn

Analyst best performing recommendations are on XLRN (ACCELERON PHARMA).
The best stock recommendation documented was for XLRN (ACCELERON PHARMA) at 3/22/2021. The price target of $132 was fulfilled within 2 days with a profit of $11.64 (8.1%) receiving and performance score of 40.52.

Average potential price target upside

of $191.58 (36.02%) on REGN (REGENERON PHARMACEUTICALS).
of $128.79 (27.51%) on LLY (ELI LILLY AND COMPANY).
of $57.37 (37.72%) on AMGN (AMGEN).

ALKS Alkermes Plc ALNY Alnylam Pharmaceuticals ALXN Alexion Pharmaceuticals AMGN Amgen ARVN Arvinas BIIB Biogen BPMC Blueprint Medicines Corp CELG Celgene FGEN FibroGen GILD Gilead Sciences LLY Eli Lilly and Company MRK Merck mpany OGN Organon PFE Pfizer REGN Regeneron Pharmaceuticals RVNC Revance The TBIO Telesis Bio AGIO Agios Pharm VRTX Vertex Pharmaceuticals ABBV AbbVie BMY Bristol-Myers Squibb Company CLVS Clovis Oncology JNJ Johnson & Johnson RPRX Royalty Pharma Plc UTHR United Therapeutics XLRN Acceleron Pharma NTLA Intellia Therapeutics AGN Allergan plc CCCC C4 Therapeutics CRSP Crispr Therapeutics AG CTMX CytomX Therapeutics ITMN InterMune MGTA Magenta Therapeutics RCUS Arcus Biosciences NRIX Nurix Therapeutics BHVN Biohaven Pharmaceutical Holding Co Ltd BNTX BioNTech SE ALMS Alumis Common Stock PRME Prime Medicine, Common Stock ISEE IVERIC bio MRNA Moderna BHG Bright Health Group GPCR Structure Therapeutics American Depositary Shares

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Uy Ear (MIZUHO)